作者:李杰教授 翻译:同写意团队 杰克说药是著名药史专家Jie Jack Li(李杰)教授专为同写意打造的药林外史精品专栏,将讲述一个个药物发现背后的故事。李杰教授现为上海睿智的副总裁,先后出版了30本有机和药物化学方面的书籍以及药物发现史,其中10本与诺奖得主E. J. Corey合作完成。其《Blockbuster Drugs》一书获 2015 Alpha Sigma Nu Science Book 奖,并被翻译成中文出版,深受欢迎。 开设写意专栏,请联系同写意秘书处(微信号tongxieyimishuchu)
参考文献(向下滑动查看更多) 1. (a) Garrido, A.; Lepailleur, A.; Mignani, S. M.; Dallemagne, P.; Rochais, C. hERG toxicity assessment: Useful guidelines for drug design. Eur. J. Med. Chem. 2020, 195, 112290. (b) Leishman, D. J.; Rankovic, Z. Drug Discovery vs hERG Topics in Medicinal Chemistry 2015, 9, 225259. (c) Rampe, D.; Brown, A. M. A history of the role of the hERG channel in cardiac risk assessment. J. Pharmacol. Toxicol. Methods 2013, 68, 13–22. 2. Wenlock, M. C.; Austin, R. P.; Davis, A. M.; Leeson, P. D. A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs. J. Med. Chem. 2003, 46, 12501256. 3. Johansson, A.; Löfberg, C.; Antonsson, M.; von Unge, S.; Hayes, M. A.; Judkins, R.; Ploj, K.; Benthem, L.; Linden, D.; Brodin, P.; et al. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. J. Med. Chem. 2016, 59, 2497–2511. 4. Biftu, T.; Sinha-Roy, R.; Chen, P.; Qian, X.; Feng, D.; Kuethe, J. T.; Scapin, G.; Gao, Y. D.; Yan, Y.; Krueger, D.; et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J. Med. Chem. 2014, 57, 3205−3212. 5. Deng, Q.; Lim, Y.-H.; Anand, R.; Yu, Y.; Kim, J.-H.; Zhou, W.; Zheng, J.; Tempest, P.; Levorse, D.; Zhang, X.; Greene, S.; Mullins, D.; Culberson, C.; Sherborne, B.; Parker, E. M.; Stamford, A.; Ali, A. Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett. 2015, 25, 2958–2962. 6. Tang, H.; Zhu, Y.; Teumelsan, N.; Walsh, S. P.; Shahripour, A.; Priest, B. T.; Swensen, A. M.; Felix, J. P.; Brochu, R. M.; Bailey, T.; et al. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure. ACS Med. Chem. Lett. 2016, 7, 697–701. 7. Wishka, D. G.; Walker, D. P.; Yates, K. M.; Reitz, S. C.; Jia, S.; Myers, J. K.; Olson, K. L.; Jacobsen, E. J.; Wolfe, M. L.; Groppi, V. E.; et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J. Med. Chem. 2006, 49, 44254436. 8. Singh, S. B.; Kaelin, D. E.; Wu, J.; Miesel, L.; Tan, C. M.; Meinke, P. T.; Olsen, D.; Lagrutta, A.; Bradley, P.; Lu, J.; et al. Oxabicyclooctane-Linked Novel Bacterial Topoisomerase Inhibitors as Broad Spectrum Antibacterial Agents. ACS Med. Chem. Lett. 2014, 5, 609–614. 9. Huscroft, I. T.; Carlson, E. J.; Chicchi, G. G.; Kurtz, M. M.; London, C.; Raubo, P.; Wheeldon, A.; Kulagowski, J. J. 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: A novel series of neurokinin (NK1) antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 2958–2962. 10. Gonzalez Cabrera, D. G.; Douelle, F.; Younis, Y.; Feng, T.-S.; Le Manach, C.; Nchinda, A. T.; Street, L. J.; Scheurer, C.; Kamber, J.; Chibale, K.; et al. Structure–Activity Relationship Studies of Orally Active Antimalarial 3,5-Substituted 2-Aminopyridines. J. Med. Chem. 2012, 55, 11022−11030. 11. Rampe, D.; Wible, B.; Brown, A. M.; Dage, R. C. Effect of terfenadine and its metabolites on a delayed rectified K+ channel cloned from human heart. Mol. Pharmacol. 1993, 44, 1240–1245.
|
|